

Ann M Ginsberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4454169/publications.pdf>

Version: 2024-02-01

15
papers

1,750
citations

758635

12
h-index

1058022

14
g-index

15
all docs

15
docs citations

15
times ranked

1944
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention of <i>M. tuberculosis</i> Infection with H4:IC31 Vaccine or BCG Revaccination. <i>New England Journal of Medicine</i> , 2018, 379, 138-149.	13.9	532
2	Final Analysis of a Trial of M72/AS01 Vaccine to Prevent Tuberculosis. <i>New England Journal of Medicine</i> , 2019, 381, 2429-2439.	13.9	350
3	Phase 2b Controlled Trial of M72/AS01 Vaccine to Prevent Tuberculosis. <i>New England Journal of Medicine</i> , 2018, 379, 1621-1634.	13.9	319
4	Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of <i>Mycobacterium tuberculosis</i> Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 638-648.	2.5	124
5	Safety and immunogenicity of the novel tuberculosis vaccine ID93+GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 287-298.	5.2	122
6	Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 220-231.	2.5	75
7	Key recent advances in TB vaccine development and understanding of protective immune responses against <i>Mycobacterium tuberculosis</i> . <i>Seminars in Immunology</i> , 2020, 50, 101431.	2.7	57
8	Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901. <i>PLoS ONE</i> , 2017, 12, e0175215.	1.1	57
9	Innovative clinical trial designs to rationalize TB vaccine development. <i>Tuberculosis</i> , 2015, 95, 352-357.	0.8	37
10	Designing tuberculosis vaccine efficacy trials – lessons from recent studies. <i>Expert Review of Vaccines</i> , 2019, 18, 423-432.	2.0	20
11	Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations. <i>Vaccine</i> , 2020, 38, 135-142.	1.7	20
12	Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines. <i>Communications Biology</i> , 2020, 3, 563.	2.0	14
13	Diagnostic Accuracy of Early Secretory Antigenic Target-6-Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube. <i>Clinical Infectious Diseases</i> , 2019, 69, 1724-1730.	2.9	12
14	Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents. <i>Tuberculosis</i> , 2013, 93, 136-142.	0.8	8
15	Tuberculosis Vaccines. , 2018, , 1095-1113.e9.		3